After meeting Warren Buffett, Danaher changed from being an aggressive corporate raider to a more patient and successful strategy
Over the past 40 years, Danaher (NYSE: DHR) has produced investment returns of about 200,000 percent, surpassing the overall stock market by multiple multiples. Although the company is still not as well-known as the big tech companies, it has one of the best records in the world for generating value for investors. Since entering the manufacturing sector in 1984, the company has mastered a methodical approach to purchasing and enhancing businesses, turning a small amount into a fortune.
This company demonstrates how even the least promising assets can be transformed into a potent competitive advantage with a consistent focus on process. When the founders switched from corporate raiding to a more patient model of long-term compounding, the company transformed from its early days as a failing real estate company to its current position as a top supplier of medical equipment. One must first consider the lessons learned during this company's risky beginnings in order to comprehend its current success.
Danaher started out as DMG, a real estate investment trust that had experienced financial difficulties by the early 1980s. Mitchell and Steven Rales, two aspirational young brothers, purchased the company in 1984 and used it as a platform for aggressive dealmaking. The brothers purchased unpopular industrial businesses and concealed profits from the tax authorities by using high-yield debt and the trust's accumulated tax losses. At this point, the business was essentially a machine built to quickly repay loans. The plan was altered in 1985 following a botched attempt to acquire the Scott Fetzer Company. This hostile acquisition attempt resulted in a public confrontation between two distinct investment philosophies. The Rales brothers made a sizable offer, but Warren Buffett, the renowned CEO of Berkshire Hathaway, made a friendlier, lower offer that the owners preferred. They rejected the Rales' aggressive tactics in favor of his plan for the company, so they went with the lower offer. It was similar to a homeowner selecting a buyer who wants to raise a family in their cherished home instead of an investor who wants to convert it into a complex of apartments.
BFIA problems nowadays. A.
Danaher learned from Warren Buffett.
The brothers learned from this failed attempt that animosity and excessive debt frequently destroyed the very value they were trying to obtain. They started pursuing companies with a long-lasting competitive advantage that they could maintain for decades as a result of this loss. The Rales brothers were fishing at Danaher Creek in Montana when this change took place. Asset-stripping was abandoned in favor of the river's name. The company started to change from being a conglomerate of niche plays to a collection of unrelated businesses. Danaher used a consistent strategy to spur growth over many years by focusing on businesses that held dominant positions in small markets. Securing appealing deals was still crucial, but the focus shifted from financing issues to increasing profit margins and bolstering the competitive positions of recently acquired companies.
By 1990, the brothers had successfully transformed Danaher into an expert investment machine. In order to become board members and serve as stewards of the business rather than its day-to-day managers, Mitchell and Steven Rales left their executive positions. The founders completely concentrated on the larger investment strategy by employing qualified executives to manage operations. As a result, Danaher was able to develop into a platform for the acquisition and careful management of superior businesses. The company needed a strict procedure to make sure these new acquisitions improved after the purchase, even though the strategy was established.
The Danaher Business System, or DBS, allowed Danaher to overcome this operational difficulty. This framework acts as the organization's primary operating system. When Toyota outperformed American automakers in the late 1980s, the leadership looked to Japan for an explanation. They came upon the idea of kaizen, or ongoing development. Ironically, Danaher was essentially repatriating US ideals because Japanese corporations had embraced American business practices to develop kaizen. Danaher's bosses adopted this as a universal management philosophy, whereas other Western companies saw it as a tool for the factory floor. From the headquarters to the factories, they implemented the idea throughout the entire company.
The system rests on four central pillars: people, plan, process and performance. This framework requires a culture in which employees prioritize execution over result analysis. This strategy avoids the typical corporate "analysis paralysis" trap. One crucial element is "compass management," or hoshin kanri. This guarantees that every aspect of the company is working toward the same objective. It ensures that everyone is working toward the same goal by coordinating the board's strategy with each employee's daily responsibilities.
Rather than being merely a manual or newsletter that people might disregard, DBS functions as an underlying philosophy ingrained in every unit's operations. To find and get rid of waste, even the board members frequently spend whole weeks organizing kaizen events on factory floors. The company remains rooted in reality by concentrating on the location of the work, or gemba as it is known in Japanese. This dedication to procedure guarantees that each acquisition rapidly advances to produce higher margins and steady growth. The company has been able to switch industries without losing its competitive edge thanks to this internal engine.
Danaher has shifted its focus from strictly industrial businesses to sectors with sustained competitive advantages, particularly diagnostics and life sciences. Instead of taking on the risks involved in drug development, the company uses a "picks-and-shovels" approach, selecting the companies that offer the necessary instruments for research. A pharmaceutical company may lose everything if they are unable to develop a new treatment. Regardless of which particular medication is approved, Danaher provides laboratories with the filters and resins they require. As a result, there is a consistent flow of income linked to the expansion of healthcare worldwide.
A large portion of the expansion is driven by the biotechnology sector. The company is the leading manufacturer of monoclonal antibodies under the brands Cytiva and Pall. These sophisticated medications, which were essential during the pandemic, treat conditions like cancer and migraines. Additionally, they are used in routine laboratory testing, particularly pregnancy tests. The equipment is incorporated into the actual process of making drugs. Once a medicine wins regulatory approval, the specific filters and components used to produce it are locked in. A lengthy and expensive review of the entire factory process would be necessary to switch to a competing supplier. An analogous advantage is provided by the diagnostics division. As a result, future sales have a high level of certainty. By focusing on non-discretionary health trends, the company's long-term risk profile has decreased and it shifts away from the erratic cycles of heavy industry toward a more consistent source of income.
A machine for professional acquisition.
Danaher is a professional acquisition machine that steers clear of purchasing companies merely for expansion. Rather, it employs a strict strategy to pinpoint markets in which it can establish a long-term competitive advantage. These acquisitions can be divided into two categories: bolt-ons, or smaller companies created to address particular technical gaps, and platforms, which represent foundational entries into large new industries that serve as a base for future expansion. To cut costs and share technology, the group incorporates these smaller businesses into its current divisions.
The cost of these resources is determined by a high degree of discipline. Every possible transaction is evaluated based on a stringent financial objective, which requires the company to generate a 10% return on capital invested by the fifth year. In particular, management searches for companies with low operating profits but high gross margins. A high gross margin indicates that the product is essential to the consumer. A low profit margin is a sign of ineffective business operations. This gap is where there is room for improvement. The company frequently doubles a new arrival's margins in three to five years by using the Danaher Business System.
This transition is overseen by the DBS Office. This group of internal experts assists new hires in assimilating into the corporate culture. Because of this, workers must devote 70% of their time to defining a problem and only 30% to finding a solution. This guarantees that the group addresses the underlying cause of a problem instead of just its symptoms. This explains why the success rate is so much higher than the industry average.
The company has experienced difficulties as it has grown. The acquisition of Cepheid, which gained notoriety for creating quick Covid tests, was successful in turning a specialized supplier into a world leader in diagnostics. But it was harder in other areas. One recent issue was the glut of bioprocessing inventory in 2023 and 2024. Customers placed excessive orders to prevent shortages during the pandemic. As a result, sales decreased in the post-pandemic world as those stocks were depleted. Some investors became frustrated because the firm was taken aback by how quickly this change occurred.
The organization has also been shaped by learning from internal mistakes. Subsidiary managers used to make mistakes by concentrating too much on particular tools for improvement while losing sight of the overall plan. Without making sure they were in line with the long-term plan, these managers would organize kaizen events to address small floor problems. As a result, the parent company improved its "strategic compass" to make sure that each change has a distinct goal. These difficulties compelled Danaher to enhance its forecasting and become more open in order to stop similar supply-chain shocks from happening again.
At the moment, the company is putting itself at the forefront of genomic medicine. The group hopes to standardize the process of developing new treatments by employing a platform approach. This is frequently likened to a burrito, in which the filling varies but the outer wrap stays the same. The time and expense of treating uncommon illnesses could be greatly reduced by using this technique. The company is building a digital foundation for the sector by incorporating AI. Additionally, the company can now obtain critical data directly from patients at the hospital bedside thanks to the acquisition of Masimo, a pioneer in pulse oximetry.
Given that Danaher has grown significantly since its industrial beginnings, it is unlikely that the 200,000 percent return will be repeated over the next 40 years. Even so, it continues to rank among the world's top companies for asset identification, acquisition, and management. It stands out due to its distinct culture and the strict implementation of its business system. The company is still a great option for people looking for a high-quality investment, even though the enormous profits of the past may be behind it.
Leave a comment on: What Warren Buffett taught the US company Danaher